Core Points - EUROAPI announces the resignation of Rodolfo J. Savitzky as Independent Director and Chair of the Audit Committee, effective December 31, 2025, following his appointment as Chief Financial Officer of Recipharm [1] - The search for a new Independent Director has commenced, with an expected appointment before the end of the year [1] - Savitzky expressed confidence in EUROAPI's Focus-27 plan and its position as a leading player in the active pharmaceutical ingredients (API) industry [3] Company Overview - EUROAPI focuses on reinventing active ingredient solutions to meet global customer and patient needs, with approximately 200 products in its portfolio [3] - The company operates five manufacturing sites in Europe and supplies customers in over 80 countries, emphasizing high-quality API manufacturing [4] - EUROAPI is listed on Euronext Paris under the ticker EAPI [4]

Core Insights - EUROAPI has signed a share purchase agreement for the sale of 100% of EUROAPI UK Ltd, which operates the Haverhill manufacturing site, to Particle Dynamics [1][2] - The divestment is part of EUROAPI's strategy to optimize its industrial footprint and advance its FOCUS-27 transformation plan, enhancing efficiency and focus on its strategic network [2] - The Haverhill site generated approximately 35 million euros in net sales in 2024, with nearly 80% attributed to Sanofi [2] Company Overview - EUROAPI is a leading player in active pharmaceutical ingredients, offering around 200 products and developing innovative molecules through its Contract Development and Manufacturing Organization (CDMO) activities [3] - The company operates six manufacturing sites in Europe and supplies customers in over 80 countries, emphasizing high-quality API manufacturing [4] - EUROAPI is listed on Euronext Paris under the ticker EAPI [4]